Corticosteroids, but not NSAIDs, are associated with less Alzheimer neuropathology

Neurobiology of Aging

Volumn 33, Issue 7, 2012, Pages 1258-1264

  Beeri, Michal Schnaider ^a   Schmeidler, James ^a   Lesser, Gerson T ^b   Maroukian, Maria ^a   West, Rebecca ^a   Leung, Stephanie ^a   Wysocki, Michael ^a   Perl, Daniel P ^a   Purohit, Dushyant P ^a   Haroutunian, Vahram ^a,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Jewish Home and Hospital   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Corticosteroids; Glucocorticoids; Neuritic plaques; Neurofibrillary tangles; Nonsteroidal anti inflammatory drugs (NSAIDs)

Indexed keywords

ACETYLSALICYLIC ACID; CORTICOSTEROID; DEXAMETHASONE; HYDROCORTISONE; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; PREDNISONE;

AGED; ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; APLASTIC ANEMIA; ARTHRITIS; ARTICLE; ASTHMA; AUTOPSY; BRAIN CORTEX; BRAIN TISSUE; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DEATH; DRUG USE; ECZEMA; EMPHYSEMA; ENTORHINAL CORTEX; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; PAIN; PNEUMONIA; PRIORITY JOURNAL; RHEUMATIC POLYMYALGIA; SENILE PLAQUE; WEGENER GRANULOMATOSIS;

ADRENAL CORTEX HORMONES; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FEMALE; HUMANS; MALE; NEUROFIBRILLARY TANGLES; PLAQUE, AMYLOID; TISSUE BANKS;

EID: 84861182620     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.02.011     Document Type: Article

References (43)

1. Aisen P.S., Davis K.L., Berg J.D., Schafer K., Campbell K., Thomas R.G., Weiner M.F., Farlow M.R., Sano M., Grundman M., Thal L.J. randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 2000, 54:588-593.
2. Aisen P.S., Schafer K.A., Grundman M., Pfeiffer E., Sano M., Davis K.L., Farlow M.R., Jin S., Thomas R.G., Thal L.J. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003, 289:2819-2826.
3. Aisen P.S., Schmeidler J., Pasinetti G.M. Randomized pilot study of nimesulide treatment in Alzheimer's disease. Neurology 2002, 58:1050-1054.
4. Arvanitakis Z., Grodstein F., Bienias J.L., Schneider J.A., Wilson R.S., Kelly J.F., Evans D.A., Bennett D.A. Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology 2008, 70:2219-2225.
5. Bannwarth B., Schaeverbeke T., Pehourcq F., Vernhes J.P., D'Yvoire M.B., Dehais J. Prednisolone concentrations in cerebrospinal fluid after oral prednisone. Preliminary data. Rev. Rhum. Engl. Ed. 1997, 64:301-304.
6. Benedict C., Hallschmid M., Schultes B., Born J., Kern W. Intranasal insulin to improve memory function in humans. Neuroendocrinology 2007, 86:136-142.
7. Brown E.S. Effects of glucocorticoids on mood, memory, and the hippocampus. Treatment and preventive therapy. Ann. N.Y. Acad. Sci. 2009, 1179:41-55.
8. Brugg B., Dubreuil Y.L., Huber G., Wollman E.E., Haye-Bouchaud N., Mariani J. Inflammatory processes induce beta-amyloid precursor protein changes in mouse brain. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:3032-3035.
9. De Kloet E.R., Vreugdenhil E., Oitzl M.S., Joels M. Brain corticosteroid receptor balance in health and disease. Endocr. Rev. 1998, 19:269-301.
10. Eikelenboom P., Bate C., van Gool W.A., Hoozemans J.J., Rozemuller J.M., Veerhuis R., Williams A. Neuroinflammation in Alzheimer's disease and prion disease. Glia 2002, 40:232-239.
11. Engelhart M.J., Geerlings M.I., Meijer J., Kiliaan A., Ruitenberg A., van Swieten J.C., Stijnen T., Hofman A., Witteman J.C., Breteler M.M. Inflammatory proteins in plasma and the risk of dementia: the rotterdam study. Arch. Neurol. 2004, 61:668-672.
12. Gotzsche P.C., Johansen H.K. Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Cochrane Database Syst. Rev. 2004, CD000189.
13. Grathwohl S.A., Kalin R.E., Bolmont T., Prokop S., Winkelmann G., Kaeser S.A., Odenthal J., Radde R., Eldh T., Gandy S., Aguzzi A., Staufenbiel M., Mathews P.M., Wolburg H., Heppner F.L., Jucker M. Formation and maintenance of Alzheimer's disease beta-amyloid plaques in the absence of microglia. Nat. Neurosci. 2009, 12:1361-1363.
14. Halliday G.M., Shepherd C.E., McCann H., Reid W.G., Grayson D.A., Broe G.A., Kril J.J. Effect of anti-inflammatory medications on neuropathological findings in Alzheimer disease. Arch. Neurol. 2000, 57:831-836.
15. Harkness K.A., Coles A., Pohl U., Xuereb J.H., Baron J.C., Lennox G.G. Rapidly reversible dementia in cerebral amyloid inflammatory vasculopathy. Eur. J. Neurol. 2004, 11:59-62.
16. Haroutunian V., Perl D.P., Purohit D.P., Marin D., Khan K., Lantz M., Davis K.L., Mohs R.C. Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. Arch. Neurol. 1998, 55:1185-1191.
17. Haroutunian V., Purohit D.P., Perl D.P., Marin D., Khan K., Lantz M., Davis K.L., Mohs R.C. Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease. Arch. Neurol. 1999, 56:713-718.
18. Hayden K.M., Zandi P.P., Khachaturian A.S., Szekely C.A., Fotuhi M., Norton M.C., Tschanz J.T., Pieper C.F., Corcoran C., Lyketsos C.G., Breitner J.C., Welsh-Bohmer K.A. Does NSAID use modify cognitive trajectories in the elderly?. The Cache County study. Neurology 2007, 69:275-282.
19. Holm S. A simple sequentially rejective multiple test procedure. Scand. J. Stat. 1979, 6:65-70.
20. Karssen A.M., Meijer O.C., van der Sandt I.C., De Boer A.G., De Lange E.C., De Kloet E.R. The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone. J. Endocrinol. 2002, 175:251-260.
21. Katsel P., Tan W., Haroutunian V. Gain in brain immunity in the oldest-old differentiates cognitively normal from demented individuals. PLoS One 2009, 4:e7642.
22. Kulstad J.J., McMillan P.J., Leverenz J.B., Cook D.G., Green P.S., Peskind E.R., Wilkinson C.W., Farris W., Mehta P.D., Craft S. Effects of chronic glucocorticoid administration on insulin-degrading enzyme and amyloid-beta peptide in the aged macaque. J. Neuropathol. Exp. Neurol. 2005, 64:139-146.
23. Lim G.P., Yang F., Chu T., Chen P., Beech W., Teter B., Tran T., Ubeda O., Ashe K.H., Frautschy S.A., Cole G.M. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 2000, 20:5709-5714.
24. Lucin K.M., Wyss-Coray T. Immune activation in brain aging and neurodegeneration: too much or too little?. Neuron 2009, 64:110-122.
25. Mackenzie I.R., Munoz D.G. Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology 1998, 50:986-990.
26. Martin B.K., Szekely C., Brandt J., Piantadosi S., Breitner J.C., Craft S., Evans D., Green R., Mullan M. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch. Neurol. 2008, 65:896-905.
27. McEwen B.S., Biron C.A., Brunson K.W., Bulloch K., Chambers W.H., Dhabhar F.S., Goldfarb R.H., Kitson R.P., Miller A.H., Spencer R.L., Weiss J.M. The role of adrenocorticoids as modulators of immune function in health and disease: neural, endocrine and immune interactions. Brain Res. Brain Res. Rev. 1997, 23:79-133.
28. McGeer P.L., McGeer E.G. Inflammation, autotoxicity and Alzheimer disease. Neurobiol. Aging 2001, 22:799-809.
29. Meijer O.C., De Lange E.C., Breimer D.D., De Boer A.G., Workel J.O., De Kloet E.R. Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice. Endocrinology 1998, 139:1789-1793.
30. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., Vogel F.S., Hughes J.P., van Belle G., Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41:479-486.
31. Morris J.C., Ernesto C., Schafer K., Coats M., Leon S., Sano M., Thal L.J., Woodbury P. Clinical dementia rating training and reliability in multicenter studies: the Alzheimer's Disease Cooperative Study experience. Neurology 1997, 48:1508-1510.
32. Peavy G.M., Salmon D.P., Jacobson M.W., Hervey A., Gamst A.C., Wolfson T., Patterson T.L., Goldman S., Mills P.J., Khandrika S., Galasko D. Effects of chronic stress on memory decline in cognitively normal and mildly impaired older adults. Am. J. Psychiatry 2009, 166:1384-1391.
33. Rafnsson S.B., Deary I.J., Smith F.B., Whiteman M.C., Rumley A., Lowe G.D., Fowkes F.G. Cognitive decline and markers of inflammation and hemostasis: the Edinburgh Artery Study. J. Am. Geriatr. Soc. 2007, 55:700-707.
34. Roozendaal B., McReynolds J.R., Van der Zee E.A., Lee S., McGaugh J.L., McIntyre C.K. Glucocorticoid effects on memory consolidation depend on functional interactions between the medial prefrontal cortex and basolateral amygdala. J. Neurosci. 2009, 29:14299-14308.
35. Sapolsky R.M., Pulsinelli W.A. Glucocorticoids potentiate ischemic injury to neurons: therapeutic implications. Science 1985, 229:1397-1400.
36. Schnaider B.M., Silverman J.M., Schmeidler J., Wysocki M., Grossman H.Z., Purohit D.P., Perl D.P., Haroutunian V. Clinical dementia rating performed several years prior to death predicts regional Alzheimer's neuropathology. Dement. Geriatr. Cogn. Disord. 2008, 25:392-398.
37. Sonnen J.A., Larson E.B., Walker R.L., Haneuse S., Crane P.K., Gray S.L., Breitner J.C., Montine T.J. Nonsteroidal anti-inflammatory drugs are associated with increased neuritic plaques. Neurology 2010, 75:1203-1210.
38. Sorrells S.F., Caso J.R., Munhoz C.D., Sapolsky R.M. The stressed CNS: when glucocorticoids aggravate inflammation. Neuron 2009, 64:33-39.
39. Stewart W.F., Kawas C., Corrada M., Metter E.J. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997, 48:626-632.
40. Szekely C.A., Green R.C., Breitner J.C., Ostbye T., Beiser A.S., Corrada M.M., Dodge H.H., Ganguli M., Kawas C.H., Kuller L.H., Psaty B.M., Resnick S.M., Wolf P.A., Zonderman A.B., Welsh-Bohmer K.A., Zandi P.P. No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology 2008, 70:2291-2298.
41. Tokuda T., Oide T., Tamaoka A., Ishii K., Matsuno S., Ikeda S. Prednisolone (30-60 mg/day) for diseases other than AD decreases amyloid beta-peptides in CSF. Neurology 2002, 58:1415-1418.
42. Weisman D., Hakimian E., Ho G.J. Interleukins, inflammation, and mechanisms of Alzheimer's disease. Vitam. Horm. 2006, 74:505-530.
43. Zandi P.P., Anthony J.C., Hayden K.M., Mehta K., Mayer L., Breitner J.C. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology 2002, 59:880-886.